In Vitro Permeation Test for Topical Generic Drug Development: Why Submissions Fail and How to Build Defensible Programs
As regulatory expectations for topical generic drug products continue to evolve, IVPT has become a central tool for supporting bioequivalence in ANDA submissions. But while IVPT can provide a more sensitive and scientifically meaningful alternative to clinical endpoint studies, successful execution requires more than simply following a protocol.
This new Diteba Inc. white paper examines why IVPT-based submissions can face regulatory challenges and how sponsors can build stronger, more defensible programs from method development through pivotal study design. The paper discusses common FDA observations, recurring deficiencies in IVPT submissions, and practical approaches to address method sensitivity and selectivity, donor variability, receptor solution design, skin integrity, statistical fragility, and outlier management.
The Whitepaper Highlights:
- Why IVPT has become an important tool for topical generic bioequivalence
- Common reasons IVPT-based ANDA submissions receive deficiencies
- How method development gaps can affect validation and pivotal study outcome
- The importance of receptor solution qualification, skin integrity, sampling design, and environmental controls
- Why sensitivity, selectivity, and discriminatory power should be built into the program early
- How pilot studies, sample size planning, and outlier strategy can reduce regulatory risk
For companies developing topical creams, gels, ointments, lotions, or other locally acting dermatological products, this paper provides a practical view of what regulators expect and how sponsors can avoid common IVPT pitfalls.
With deep experience in IVRT and IVPT study design, method development, validation, and regulatory submission support, Diteba Inc. helps clients build scientifically sound and FDA-aligned programs for topical drug development.
Download the white paper to learn more about building defensible IVPT programs for topical generic products. Contact us to discuss how Diteba can support your IVPT strategy, method development, validation, or ANDA submission.
Download the Whitepaper by filling out our simple form that will appear in the popup window. Your download will begin immediately after.
